WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Resources > Whitepapers > Value-Based Contracting for Oncology Drugs
August 29, 2017
I'm For Real
Enter your details once to access all our information and resources
TailorMed offers the nation’s largest network of patients, providers, pharmacies, partners, and life science companies focused on ensuring all patients across all medical conditions can afford treatment.
whitePaper | June 15, 2022
To date, therapeutic advances in treating central nervous system (CNS) disorders have been incremental at best. As the global population increases and older demographics begin to make up a disproportionately larger percentage,
whitePaper | December 16, 2019
The use of FAIR (Findable, Accessible, Interoperable and Reusable) data in drug discovery and development could be transformational. But the pharma industry has been slow to embrace FAIR data — partially because of difficulties in establishing the necessary infrastructure and because of internal culture.
whitePaper | March 27, 2023
European countries have been experiencing medicine shortages due to disruptions in the supply chain. Reshoring the productions of active pharmaceutical ingredients (APIs) is considered as an approach to secure the supply.
whitePaper | April 7, 2020
The information in this document is designed to help you understand the prescription drug benefits offered under this plan and to compare these benefits to those offered by other plans. Information contained in this summary is designed to help you compare both the value and scope offormulary benefits.
whitePaper | November 18, 2022
To realize the full potential of RWD, we must put the patient at the center and truly understand each patient’s unique circumstances over time. It’s certainly a tall order when the data we need is scattered across siloed systems and guarded by applicable and necessary patient privacy regulations.
whitePaper | July 8, 2022
Particulates are ubiquitous in parenteral drug products and remain a concern throughout their development and production1–3. These particles must be monitored to satisfy.
Conference
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE